MedTrace Logo

Gene Transfer for Cancer Pain

NCT00804076 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-02-19

No results posted yet for this study

Summary

The primary purpose of this study is to examine the safety of NP2 (a nonreplicating HSV-based vector expressing enkephalin) in patients with cancer pain. The secondary purpose is to evaluate efficacy.

Conditions

  • Cancer Pain

Interventions

BIOLOGICAL

NP2

Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.

Sponsors & Collaborators

  • Diamyd Inc

    lead INDUSTRY

Principal Investigators

  • David J Fink, MD · University of Michigan Department of Neurology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-11-30
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00804076 on ClinicalTrials.gov